title: Anti-HIV therapy update.
abstract: Recently there have been good and bad news from the anti-HIV drug development front. First the good news, the Food and Drug Administration (FDA) recently approved tenofovir (Viread) for the treatment of HIV disease. This is welcome news for people who need a new drug to put together a second or third line regimen and may even be an important new choice for first line therapy. Additionally, a long awaited expanded access program for the fusion inhibitor T-20 (pentafuside) has been announced. The bad news is that the program is so small that it will provide drug to only 168 people in the United States, in the first stage of the program. This will be gradually increased as more drug becomes available but a wider expanded program is still a long way off.
mesh_terms: D019380:Anti-HIV Agents / Q000627:therapeutic use*; D017277:Drug Approval / Q000331:legislation & jurisprudence; D006801:Humans; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D019380:Anti-HIV Agents